LncRNA HOXA‐AS3 promotes the malignancy of glioblastoma through regulating miR‐455‐5p/USP3 axis

Abstract

Glioblastoma multiforme (GBM) is a fast-growing type of aggressive and lethal primary brain tumour. 1,2 Because the pathologic mechanisms of GBM are not fully understood, more research is needed to identify effective predictive biomarkers and therapeutic targets for GBM. 2,3 Emerging studies, supported by whole-genome sequencing technology and microarray assays, have shown long non-coding RNAs (lncRNAs) to be key regulatory transcripts. 4 LncRNAs are classified

LncRNA HOXA-AS3 promotes gastric cancer progression by regulating miR-29a-3p/LTβR and activating NF-κB signaling

“…4 a, b). Such cytoplasmic localization is consistent with the ability of HOXA-AS3 to serve as a ceRNA for specific miRNAs, as has previously been shown to occur in the context of HCC, glioma, and atherosclerosis [ 9 , 12 , 20 ]. Using the Starbase v3.0 ( http://starbase.sysu.edu.cn ) platform [ 21 ], we identified three putative HOXA-AS3 targets in GC (miR-29a-3p, miR-29b-3p and miR-29c-3p).…”

“…There is also evidence that HOXA-AS3 can mediate cisplatin resistance, making it a viable therapeutic target in non-small cell lung cancer (NSCLC) [ 11 ]. HOSX-AS3 has also been confirmed to serve as a competing endogenous RNA (ceRNA) in HCC and glioma [ 9 , 12 ], whereas its functional role in GC remains to be described.…”

LncRNA HOXA-AS3 Promotes Gastric Cancer Progression by Regulating miR-29a-3p/LTβR and Activating NF-κB Signaling

“…4a). Such cytoplasmic localization is consistent with the ability of HOXA-AS3 to serve as a ceRNA for speci c miRNAs, as has previously been shown to occur in the context of HCC, glioma, and atherosclerosis [12,13,21]. Using the Starbase v3.0…”

“…There is clear evidence that HOXA-AS3 can function as a ceRNA in the context of HCC, glioma, and atherosclerosis [12,13,21]. In HCC, this lncRNA controls the miR-29c/BMP1 axis and thereby promotes tumor cell proliferation, EMT, and metastasis via activating MEK/ERK signaling [9].…”

“…There is also evidence that HOXA-AS3 can mediate cisplatin resistance, making it a viable therapeutic target in non-small cell lung cancer (NSCLC) [11]. HOSX-AS3 has also been con rmed to serve as a competing endogenous RNA (ceRNA) in HCC and glioma [12,13], whereas its functional role in GC remains to be described.…”